NCT05526755进行中（未招募）2 期
An Open-label, Single-arm, Phase II, Multinational, Multicentre Study to Assess the Efficacy and Safety of 5 Years of Osimertinib in Participants With EGFRm-positive Stage II-IIIB NSCLC, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 发起方
- AstraZeneca
- 入组人数
- 188
- 试验地点
- 56
- 主要终点
- Estimate the Efficacy of Osimertinib as Measured by Disease Free Survival (DFS) [Common EGFRm Cohort].
研究概览
简要总结
To assess the efficacy and safety of osimertinib in participants with EGFRm positive stage II-IIIB NSCLC, following complete tumour resection with or without adjuvant chemotherapy.
详细描述
This is a phase 2 open-label study to assess the efficacy and safety of osimertinib in participants with stage II-IIIB NSCLC with sensitising EGFR mutations. The study is designed to evaluate 5 years of adjuvant osimertinib therapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 130 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female aged at least 18 years.
- •Histologically confirmed diagnosis of primary NSCLC on predominantly non-squamous histology.
- •Magnetic Resonance Imaging (MRI) or contrast computed tomography (CT) scan of the brain.
- •Participants must be classified post-operatively as Stage II, IIIA, or IIIB on the basis of surgical pathologic criteria.
- •Confirmation by the local laboratory that the tumour harbours one of the two common EGFR mutations (Ex19del, L858R), either alone or in combination with other EGFR mutations including de novo EGFR mutation resulting in substitution of threonine with methionine at amino acid position 790 in exon 20 of EGFR (T790M) or uncommon EGFR mutations G719X, S768I, and L861Q, either alone, in combination with each other, or in combination with other uncommon EGFR mutations (excluding all exon 20 insertions) (Uncommon EGFRm Cohort).
- •Complete surgical resection of the primary NSCLC is mandatory. All gross disease must have been removed at the end of surgery. All surgical margins of resection must be negative for tumour.
- •Complete recovery from surgery and standard post-operative therapy (if applicable) at start of study intervention.
- •World Health Organisation Performance Status of 0 to
- •Female participants must be using highly effective contraceptive measures, and must have a negative pregnancy test prior to start of dosing if of childbearing potential.
- •Male participants must use effective barrier contraception.
排除标准
- •Major surgery (including primary tumour surgery, excluding placement of vascular access) within 4 weeks prior to the first dose of study drug.
- •Participants currently receiving medications or herbal supplements known to be strong inducers of CYP3A4 (at least 3 weeks prior to first dose).
- •Participants who have had only segmentectomies or wedge resections.
- •History of other malignancies, except: adequately treated non-melanoma skin cancer, curatively treated in situ cancer, or other solid tumours curatively treated with no evidence of disease for > 5 years before the start of study intervention.
- •Treatment with any of the following:
- •Pre-operative or post-operative or planned radiation therapy for the current lung cancer.
- •Pre-operative (neo-adjuvant) platinum-based or other chemotherapy.
- •Any prior anti-cancer or immunological therapy, including investigational therapy, for treatment of NSCLC other than standard platinum-based doublet post-operative adjuvant chemotherapy.
- •Prior treatment with neoadjuvant or adjuvant EGFR tyrosine kinase inhibitor (TKI).
- •Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product, or previous significant bowel resection that would preclude adequate absorption of osimertinib.
- •Any of the following cardiac criteria:
- •Mean resting corrected QT (QTc) interval > 470 msec, obtained from 3 electrocardiograms (ECGs).
- •Any clinically important abnormalities in rhythm, conduction, or morphology of resting ECG.
- •Any factors that increase the risk of QTc prolongation or risk of arrhythmic events.
- •Heart failure, congenital long QT interval (QT) syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age in first-degree relatives or any concomitant medication known to prolong the QT interval and cause Torsades de Pointes (TdP).
- •Past medical history of interstitial lung disease (ILD), drug-induced ILD, radiation pneumonitis that required steroid treatment, or any evidence of clinically active ILD.
- •Inadequate bone marrow reserve or organ function.
- •Women who are breastfeeding.
研究组 & 干预措施
Osimertinib
Experimental
Participants will receive osimertinib (AZD9291).
干预措施: Osimertinib 80 mg/40 mg (Drug)
结局指标
主要结局
Estimate the Efficacy of Osimertinib as Measured by Disease Free Survival (DFS) [Common EGFRm Cohort].
时间窗: From date of first dose until date of disease recurrence or death (by any cause in the absence of recurrence), up to approximately 5 years. Assessed at 5 years.
Defined as time from date of first dose until disease recurrence, or death due to any cause in the absence of recurrence.
次要结局
- Disease Free Survival Rate at 3, 4 and 5 Years (Uncommon EGFRm Cohort)(From date of first dose until date of disease recurrence or death (by any cause in the absence of recurrence), up to approximately 5 years. Assessed at 3 years, 4 years, and 5 years.)
- DFS Rate at 3 and 4 Years (Common EGFRm Cohort)(From date of first dose until date of disease recurrence or death (by any cause in the absence of recurrence), up to approximately 5 years. Assessed at 3 years, and 4 years.)
- Overall Survival (OS) [Common EGFRm Cohort](From date of first dose until the date of death due to any cause, up to approximately 5 years. Assessed at 3 years, 4 years, and 5 years.)
- Safety and tolerability in overall population (Common EGFRm Cohort and Uncommon EGFRm Cohort)(From date of first dose up to approximately 5 years)
- Recurrence events in overall population (Common EGFRm Cohort and Uncommon EGFRm Cohort)(From date of first dose up to approximately 5 years)
研究者
研究点 (56)
Loading locations...
相似试验
尚未招募
2 期
A Study to Evaluate the Efficacy of Osimertinib in Patients With EGFR-sensitive Mutated Non-small Cell Lung Cancer Progression After Receiving Adjuvant Targeted Therapy Following Radical SurgeryLung NeoplasmsLung Cancer, Nonsmall CellNCT06530719Jin Ying54
进行中（未招募）
2 期
First-line Treatment With Osimertinib in EGFR-mutated Non-small Cell Lung CancerLung CancerNCT03804580Vestre Viken Hospital Trust100
已完成
2 期
Exploring the Theragnostic Value of Osimertinib in EGFR-mutated Lung Cancer (THEROS)EGFR T790MFDG-PETNSCLCNCT03810066University Hospital, Essen16
招募中
2 期
Osimertinib Therapy After Resection in High-risk Stage I EGFRm NSCLC (OSTAR)NSCLC, Stage INCT05686434Tianjin Medical University Cancer Institute and Hospital65
进行中（未招募）
3 期
A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour ResectionNon-Small Cell Lung CancerNCT05120349AstraZeneca390